依托孕烯皮下埋植剂治疗子宫腺肌病的疗效及安全性观察

doi:10.3969/j.issn.1006-6233.2017.12.016

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1392 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate the efficacy and safety of a etonogestrel-releasing implant in treatment of adenomyosis. Methods: 30 cases of adenomyosis patients admitted in our hospital from January 2015 to January 2017 were selected as the research object, adopt treatment etonogestrel implants, respectively, on the fifth day after operation, first, 3, 6, and 12 months postoperatively. The analysis of the contraceptive effect, relieve dysmenorrhea degree, after months of treatment and the curative effect of adverse reactions the degree of dysmenorrhea; using visual analog scale (VAS) assessment. Results: The contraceptive rate is as high as 100%.30 cases of adenomyosis patients had different degrees of dysmenorrhea before subcutaneous implantation, and the degree of dysmenorrhea was relieved or disappeared 3 months after implantation (P＜0.05). There were 12 cases of menorrhagia, menostaxis patients treated for 1 months, 3 months, 6 months, 12 months after the endometrial thickness compared with before treatment were significantly thinner (P<0.05),the volume of uterus treated for 1 months and 3 months later was not different from that before treatment(P>0.05; treatment for 6 months and 12 months was significantly lower than before treatment(P<0.05). The major adverse effect during the follow-up period was a change in bleeding patterns. Conclusion: The treatment of adenomyosis with subcutaneous implants can effectively relieve dysmenorrhea, and can treat menorrhagia. It is safe and reliable and can be popularized in clinical practice.

Key words： Adenomyosis Adenomyosis Contraceptive efficacy Safety Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUA Hua
	CAO Xixia
	ZHU Hui

Cite this article:

HUA Hua,CAO Xixia,ZHU Hui. The Safety and Clinical Efficacy of Etonogestrel-releasing Implant in the Treatment of Adenomy[J]. HeBei Med, 2017, 23(12): 1991-1993.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.12.016 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I12/1991

[1] 张信美,许泓,黄秀峰,等.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的长期疗效观察[J].中华妇产科杂志,2009,44(9):694~696.
[2] 彭存旭,李景刚,郝贤华,等.腹腔镜下多术式联合治疗子宫腺肌病的临床观察[J].实用妇产科杂志,2014,30(6):475~478.
[3] 刘佩姬,张朝红,廖翠英,等.新型单根皮下埋植剂依托孕烯的临床分析[J].现代医院,2016,16(11):1578~1580.
[4] 平晟旻,顾逢春,张祎.依托孕烯单根皮下埋植剂(Implanon(R))的月经模式变化和对痛经治疗的临床研究[J].生殖与避孕,2017,37(2):143~145.
[5] Randel A,Guidelines for the use of long-acting reversible contraceptives[J].Am Fam Physician,2012,85:403~404.
[6] American College of Obstetricians and Gynecologists AC'OU Practice Bulletin No.121:Long-acting reversible contraception:Implants and intrauterine devices[J].Obstet Gynecol, 2011,118:184~196.
[7] 吴喜梅,杨燕,胥玉梅,等.依托孕烯皮下埋植剂的临床应用[J].生殖医学杂志,2016,25(11):1044~1047.
[8] 周建政,李晶.依托孕烯单根皮下埋植剂Implanon治疗子宫腺肌病25例疗效观察[J].临床医药实践,2014(8):594~596.
[9] Bhatia P, Nangia S, Aggarwal S, et al. Implanon: Subdermal Single Rod Contraceptive Implant[J].Journal of Obstetrics & Gynecology of India, 2011, 61(4):422~425.
[10] 覃太洲,谢利,乔林,等.依托孕烯皮下埋植剂使用现状调查研究[J].实用妇产科杂志,2015,31(3):217~220.
[11] 姬萌霞,彭萍,刘鹏飞,等.Implanon皮下埋植避孕剂出血模式及副作用临床分析[J].生殖医学杂志,2016,25(5):401~405.
[12] Guiahi M, Mcbride M, Sheeder J, et al. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial[J].Obstetrics & Gynecology, 2015, 126(3):508~513.
[13] 吕榜权,蒋丽,陈玉梅,等.人工流产后口服屈螺酮炔雌醇片、放置宫内节育环、依托孕烯皮下埋植剂的避孕效果及安全性对比研究[J].广西医学,2016,38(8):1068~1071.
[14] 杨炜炜,李晶晶.依托孕烯单根皮下埋植避孕效果及对月经模式的影响[J].中国妇幼保健,2016,31(9):1926~1928.
[15] 钱翠凤,黄紫蓉.皮下埋植避孕剂的研究进展[J].国际生殖健康/计划生育杂志,2013,32(2):107~110.